Cannabis Science Inc (OTCMKTS:CBIS) Takes A Step Forward

By Steven Goodstein / in Marijuana, Medical / on Tuesday, 13 Dec 2016 12:12 AM

Dr. Wilfred F. Ngwa, the Harvard Director of Global Health Catalyst at the DF/HCC, stated that Cannabis Science Inc (OTCMKTS:CBIS) presentation was a huge success. This development will lead to beneficial partnership opportunities between the firm and Harvard Medical School.
The expert view

Dr. Ngwa said that they were pleasantly surprised with the clearly targeted missions, direct plan of action and knowledge depth offered by Cannabis Science. They discussed the drug development success and advancement the company had made so far. Partnerships between renowned scientists and CBIS team at the DF/HCC are anticipated to bring in-depth knowledge of the potential effectiveness of cannabinoids in the cancer treatment and also other chronic diseases. Dr. Ngwa added that they will outline the motivations for research partnership with a viewpoint of successfully publishing details in a renowned peer-reviewed medical journal.

Mr. Dabney participated in the talks, and together with Melvin F. Foote and Dr. Allen A. Herman, the CMO of Cannabis Science delivered a comprehensive overview of the firm and its “Cannabis Science Research” Foundation. It covered details on cannabinoids treatment, targeting different critical ailments and validating the ability to destroy cancer cells and improve the therapeutic management of different types of cancers. It engaged the Harvard faculty members in deliberating approaches to establishing a research and drug development alliance between Dana Farber/Harvard Cancer Center and Cannabis Science.

Dr. Herman commented that during the roundtable talks, they received an opportunity to discuss prospective pre-clinical, and clinical research plans and objectives with the DF/HCC scientists. The drug advancement targeting will be implemented by the new association and is projected to alter the dynamics of phyto-pharmaceutical progression, particularly in the segments of clinical study design and program implementations.

Raymond C. Dabney, the CEO and President of Cannabis Science, said that with the support of renowned team of scientists of a prestigious cancer research institution, the company hopes to launch new therapies from research to FDA nod much more quickly. The partnership strength is underscored by an in-depth knowledge of the acceptance procedures at the Food and Drug Administration.